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6/j.bPeripheral blood stem cells (PBSCs) are increasingly used as the graft source in allogeneic hematopoietic cell
transplantation. We compared long-term outcome after unrelated donor transplantation of 85 consecutive
patients with acute myelogenous leukemia or myelodysplastic syndrome regarding disease status (early dis-
ease [CR1, refractory anemia); n 5 25 and advanced/active disease [.CR1, .refractory anemia]; n 5 60)
who were treated with conventional conditioning regimens followed by bone marrow (BM) or PBSC grafts.
Graft-versus-host disease prophylaxis consisted mainly of cyclosporine A, short-course methotrexate, and
anti-T-lymphocyte globulin. After a median follow-up of 118 months (68-174), the 10-year event-free survival
rate after peripheral blood stem cell transplantation (PBSCT) was 54.8% (95% confidence interval [CI],
39.7%-69.8%), and after bone marrow transplantation (BMT), it was 27.9% (14.5%-41.3%; P\.004). In the
advanced/active disease group, the 10-year event-free survival rate after PBSCT was 50% (30.8%-69.2%),
and after BMT, it was 23.5% (9.3%-37.8%; P\ .007). Non relapse mortality was less after PBSCT than
BMT (14.3% vs 30.2%), respectively. In multivariate Cox regression analysis, PBSCT showed a better overall
survival (OS; hazard ratio [HR], 0.43; 95% CI, 0.23-0.79; P5 .007) compared to BMT; unfavorable/unknown
prognostic impact cytogenetic abnormalities were an adverse factor for all patients (HR, 2.202; 95% CI, 1.19-
4.06; P5 .011). In patients with advanced disease, the use of PBSCs showed a significant favorable outcome
via multivariate analysis (HR, 0.49; 95% CI, 0.24-0.99; P 5 .046). Outcome of acute myelogenous leukemia/
myelodysplastic syndrome after unrelated hematopoietic cell transplantation is adversely affected by cytoge-
netic abnormalities and state of remission at hematopoietic cell transplantation. PBSC as a graft source has
a significant favorable influence on survival.
Biol Blood Marrow Transplant 18: 894-902 (2012)  2012 American Society for Blood and Marrow TransplantationKEY WORDS: Allogeneic HCT, URD transplantation, BMT, PBSCTepartment of Hematology & Oncology, Albert
niversity Medical Center Freiburg, Hugstetter Str.
06 Freiburg, Germany; and 2Clinical Trials Unit,
Medical Center Freiburg, Elsaesser Str. 2;
reiburg, Germany.
re: See Acknowledgments on page 901.
ss: Patras University Medical School Rion/Patras
ece.†Present address: National Center for Tumours,
eimer Feld 350, D-69120 Heidelberg, Germany.
e and reprint requests: J€urgen Finke, MD, Albert
niversity Medical Center, Department of
y/Oncology, Allogeneic Stem Cell Transplantation
ugstetter Str. 55, D-79106 Freiburg, Germany
ergen.Finke@uniklinik-freiburg.de).
, 2011; accepted November 14, 2011
an Society for Blood and Marrow Transplantation
.00
bmt.2011.11.017INTRODUCTION
Over the last decade, peripheral blood stem cells
(PBSCs) have increasingly been used as the graft
source in allogeneic hematopoietic cell transplantation
(HCT) compared to bone marrow (BM). Reasons are
faster engraftment, [1-3] harvesting without general
anesthesia, higher counts of stem cells, and improved
disease control by enhanced graft-versus-leukemia
(GVL) effect. This is accompanied by more frequent
and extensive chronic graft-versus-host disease
(cGVHD) [1,4,5]. These data have been primarily
collected after sibling transplantation. In a meta-
analysis involving nine randomized trials and 1111
patients with sibling transplantation comparing
PBSC and BM as graft sources, patients with advanced
disease benefited from peripheral blood stem cell
transplantation (PBSCT) with improved disease-free
survival (DFS) and overall survival (OS) [6]. On the
Table 1. Patient Characteristics
BMT (n 5 43) PBSCT (n 5 42)
Age in median 36.2 years (17-55) 43.5 years (18-58)
Male:female 22:21 20:22
Number
CR1/RA Advanced CR1/RA Advanced
No. % No. % No. % No. %
9 (21) 34 (79) 16 (38) 26 (62)
Diagnosis
de novo AML 6 (14) 23 (58) 13 (31) 13 (31)
t+s+ts AML 1 (2) 9 (21) 2 (5) 10 (24)
MDS RA 1 (2) 1 (2)
MDS >RA 1 (2) 2 (4) 3 (8)
Cytogenetics
Favorable 1 (2) 1 (2)
Intermediate 4 (12) 12 (35) 3 (31) 14 (32)
Unfavorable 1 (2) 10 (23) 6 (14) 9 (21)
Unknown dignity 3 (7) 5 (12) 7 (16)
Unknown 1 (2) 6 (21) 2 (5)
Remission at TX
CR 1 8 (19) 15 (36)
Untreated 1 (2) 4 (9) 1 (2) 5 (5)
CR 2/3 5 (12) 3 (8)
REL >1 16 (37) 8 (20)
PIF 9 (21) 10 (24)
Conditioning
BU/CY containing 9 (21) 30 (70) 16 (38) 26 (62)
TBI/CY + VP16 4 (9)
GVHD prophylaxis
CSA +
Mini-MTX 1 16 (37) 1 (2) 22 (52)
MTX/+PRED 2/6 6/9 14/1 3 (7)
Other 3 (7) 1 (2)
ATG-F <60 mg/kg 7 (16) 1 (2) 24 (57)
ATG-F $60 mg/kg 9 (21) 27 (63) 15 (36) 2 (4)
CMV serology
Donor (D) pos 2 (4) 3 (7) 2 (5)
Recipient (R) pos 4 (9) 14 (32) 10 (24) 11 (26)
Both pos 2 (4) 10 (23) 1 (2) 6 (14)
Negative R&D 1 (2) 7 (16) 4 (10) 7 (17)
Blood group
No mismatch 2 (4) 8 (19) 5 (12) 8 (19)
Minor mismatch 1 (2) 14 (32) 5 (12) 10 (24)
Major mismatch 6 (14) 12 (28) 6 (14) 8 (20)
Rh-G-CSF post-TX 9 (21) 32 (74) 11 (26) 22 (52)
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children suggested a worse outcome after transplanta-
tion from a sibling donor when PBSCwas compared to
BM [7,8]. Recipient and donor factors such as gender,
[8] cytomegalovirus (CMV) serology, [9] and donor
age, [10,11] as well as the transplanted cell dose may
have contributed to the different outcome in addition
to the actual graft source. At least in
BM transplantation, a higher marrow-cell dose is an
important factor to improve survival rates [12-14].
This association is less clear when PBSC grafts were
used [15].
Few data are available comparing bone marrow
transplantation (BMT) and PBSCT after volunteer
unrelated donor (URD) transplantation. Transplanta-
tion with PBSC as a graft source from HLA identical
URD revealed improved DFS compared to BMT in
patients with chronic myelogenous leukemia (CML)
in the first chronic phase (CP1), [16] or no difference
in OS or DFS, but more cGVHD after PBSCT
in patients with various other hematological malignan-
cies [17-19]. A randomized trial showed the safety
of URD transplantation using anti-T-lymphocyte
globulin (ATG-F) as graft-versus-host disease
(GVHD) prophylaxis after PBSCT [20].
We retrospectively analyzed the outcome after
matched and mismatched URD transplantation with
respect to disease status (early vs advanced/active dis-
ease) and graft source (BM vs PBSC) in patients with
acute myeloid leukemia (AML) or myelodysplastic
syndrome (MDS). All patients received their first allo-
geneic hematopoietic cell transplantation (alloHCT)
after standard high-dose conditioning. Regarding OS
and event-free survival (EFS), the importance of
disease-related factors like cytogenetics, CMV status
or GVHD prophylaxis are shown. The presented
data have an exceptionally long follow-up of 10 years.BMT indicates bone marrow transplantation; PBSCT, peripheral blood
stem cell transplantation; AML, acute myeloblastic leukemia; t, therapy
associated; s, secondary; ts, therapy-associated secondary; MDS, myelo-
dysplastic syndrome; RA, refractory anemia; TX, transplantation; CR,
complete remission; REL, relapse; PIF, persistent induction failure; BU/
CY, busulphane/cyclophosphamide; TBI, total body irradiation; VP16,
etoposide; GVHD, graft-versus-host disease; CSA, cyclosporine; MTX,
methotrexate; PRED, prednisolone; ATG-F, antithymocyteglobuline-fre-
senius; CMV, cytomegalovirus; R&D, recipient and donor; Rh-G-CSF
post-TX, granulocyte colony-stimulating factor posttransplantation.METHODS
Patient Characteristics
For this survey, we used prospectively collected
data from our University of Freiburg alloHCT data-
base and identified 85 patients; their characteristics
are listed in Table 1. Diagnoses were de novo AML
(n 5 55), therapy-related AML (n 5 4), secondary
AML (n 5 20), or MDS (refractory anemia [RA], re-
fractory anemia with excess blast [RAEB II], and
chronic myelomonocytic leukemia [CMML]; n 5 6).
Median duration of disease until transplantation was
222 days (range, 54-8876 days). The 42 female and
43 male patients had a median age of 40.1 years (range,
17-58 years). At transplantation, 11 patients were
untreated, 31 were in complete remission (CR) at
transplantation (CR1 [n5 23] or CR2/3 [n5 8]) after
chemotherapy, while 19 patients were refractory toinduction/reinduction chemotherapy and never in
CR, and 24 patients had relapsed from CR in median
after 6 months (range, 2-39 months). Reasons for
URD transplantation in patients with early disease
were induction failure (n5 3), treatment-related acute
myelogenous leukemia ([tAML] n 5 1), life-threaten-
ing cytopenias (n 5 2), myelomonoblastic leukemia
(n5 1), or cytogenetic abnormalities (n5 18). Overall,
46 patients had known cytogenetic abnormalities
with 19 patients presenting with .1 abnormality.
Cytogenetic abnormalities involved chromosomes 7
896 Biol Blood Marrow Transplant 18:894-902, 2012H. Bertz et al.(n 5 12), 3 (n 5 3), 5 (n 5 1), 9 (n 5 2), 4 (n 5 2),
t(15;17), t(9;22), -18, inv 16 (n 5 1 each), del 11 (n 5
1), 18 solely (n 5 3), and complex karyotype in three
patients. The karyotype was unknown in nine and
normal in 29 patients. According to the Cancer and
Leukemia Group B (CALGB) criteria, [21] cytogenet-
ics were classified as favorable (n 5 2), intermediate
(n5 33), unfavorable (n5 26), or unknown prognostic
impact (n 5 15). No patient had undergone previous
transplantation. Pretransplantation CMV serology
was positive in 19 patient/donor pairs, in seven cases
in donors only, and in 39 cases in patients only. Blood
group mismatch transplantation was performed in 62
cases (n 5 30 minor, n 5 32 major).
Conditioning Regimens and GVHD Prophylaxis
All patients received oral busulphan (16 mg/kg
body weight [bw]) in combination with cyclophospha-
mide (120 mg/kg; n 5 81) or fractionated total body
irradiation (TBI; 12 Gy) plus cyclophosphamide
60 mg/kg plus etoposide VP 16 60 mg/kg bw (n 5 4).
GVHD prophylaxis consisted of intravenous
cyclosporine A (CsA) starting at day -3 at a dose of
2.5 mg/kg b.i.d (trough level, 250-350 ng/mL) in com-
bination withmethotrexate ([MTX] 15mg/m2 day11,
10 mg/m2 day13, day16) (n5 25) and in 16 patients
who additionally received prednisolone, or mini-MTX
(5 mg/m2 day 11, day 13, day 16) (n 5 40). CsA was
substituted by tacrolimus in one patient. CsA or
tacrolimus were given orally as soon as the patient
was able to swallow. In addition, all patients received
ATG 20-90 mg/kg bw (ATG-F, Fresenius; Graefel-
fing; Germany) [20,22]. Standard supportive care and,
in case of CMV reactivation, pre-emptive ganciclovir
or foscarnet therapy was given as described previously
[23]. RhG-CSF (Filgrastim, Amgen, Munich,
Germany) was given to 64 of 85 patients (75%) usually
starting on day 17 until neutrophil recovery .1 
109/L. The transplantation protocols were approved
by the FreiburgUniversityMedicalCenter institutional
review board, and all patients gave written informed
consent for treatment and prospective data collection
in accordance with the Declaration of Helsinki.
Donors and Grafts
In 24 of 85 transplantations (28%), the donor was
a mismatched URD (n 5 3 .1 mismatch) (Table 2).
HLA class-I antigens (A and B) were serotyped (two
digits), and class II (DRB1 and DQB1) were analyzed
by DNA high-resolution typing (four digits) [23]. BM
was grafted in 43 of 85 patients (50%) and unmanipu-
lated PBSC in 42 of 85 patients (50%). The median
donor age was 34 years (range, 20-55 years). A woman
donated to a male recipient in 18 transplantations.
During the first half of the time period (1995-
1999), the majority of patients underwent transplanta-tion with BM (n 5 37 of 42), and from 2000 to 2004,
preferentially with PBSC (n 5 38 of 43).
The median number of white blood cells (WBCs)
transfused was 3  108/kg (range, 1.2-13.9) per
recipient bw in BMT and 11  108/kg bw (range, 1.6-
21.4) in PBSCT; the median values for CD341 and
CD31 were 2.9 (range, 0.15-7.1) and 29  106/kg
bw (range, 1.8-270) in BMT and 5.9 (range, 1.5-17)
and 305  106/kg bw (range, 110-2000) in PBSCT,
respectively.Evaluation and Statistical Analysis
Acute GVHD (aGVHD) and cGVHDs were
assessed using the criteria of Przepiorka and Shulman
[24,25]. Data were evaluated as of March 1, 2010, and
follow-up of patients was complete except for one pa-
tient (UPN 020626). OS was defined as the time from
HCT to death of any cause, and EFSwas defined as the
time from HCT to relapse or death of any cause. Ob-
servation times were censored at the date the patient
was last seen alive in case the event of interest was
not observed. OS and EFS rates were estimated and
displayed using the Kaplan-Meier method. We ana-
lyzed the influence of the following parameters on
OS in all patients and in the subgroup of patients
who underwent transplantation and had advanced-
stage disease: graft (BMT vs PBSC), sex, female donor
in male recipient, age at HCT (\/$40 years),
cytogenetics (favorable/intermediate vs unfavorable/
unknown prognostic impact), CMV positive serology
in donor and recipient, remission at HCT (early vs
advanced), match vs mismatched donor, chronic
GVHD (yes or no as a time-dependent variable),
time of transplantation (1995-1999 vs 2000-2004)
and ATG-F dose (\/$60 mg/kg). This cut-off was
used because it is the dose of the large randomized
trial. [20] Statistical analysis of OS was carried out
using univariate and multivariate Cox proportional
hazard models with SAS software version 9 (SAS Insti-
tute, Cary, NC). Univariate analyses were regarded as
a preliminary step. In the multivariate model, a back-
ward elimination procedure was performed until only
prognostic factors with P\ .20 were retained. Results
are presented as hazard ratios (HRs) with correspond-
ing 95% confidence intervals (CIs) and Wald c2 test
P values.
Group comparisons (BMT vs PBSCT) for binary
prognostic factors observed at the time of transplanta-
tion were conducted by applying the Fisher exact test.
Probabilities for the occurrence of cGVHD were
estimated using cumulative incidence rates, where
death without cGVHDwas considered as a competing
risk. Similarly, relapse mortality (RM) and nonrelapse
mortality (NRM) were regarded as competing risks,
and the respective RM and NRM probabilities were
estimated as cumulative incidence rates.
Table 2. Donor and Graft Characteristics
BMT (n 5 43) PBSCT (n 5 42)
CR1/RA (n 5 9) Advanced (n 5 34) CR1/RA (n 5 16) Advanced (n 5 26)
Mismatch TX 1 14 3 6
A, B 4 1
DR mismatch 8 1 3
DQ mismatch 1 1 2 2
>1 mismatch 2 1
Age of donor (range) 34.5 (26-45) 35.5 (21-55) 34.5 (25-41) 30.5 (20-51)
Female donor/male recipient 3 7 4 4
Graft size
WBC 108/kg bw (range) 2.8 (1.2-13.9) 3 (1.6-8.8) 9.6 (1.6-8.8) 13.1 (2.5-1.4)
CD 34  106/kg bw (range) 1.6 (0.15-5.3) 3.2 (0.25-7.1) 4.3 (1.8-17) 6.9 (1.5-16)
CD 3  107/kg bw (range) 2.9 (1.2-11) 2.85 (0.18-27) 29.5 (11-52) 33.5 (15-200)
BMT indicates bone marrow transplantation; PBSCT, peripheral blood stem cell transplantation; CR, complete response; RA, refractory anemia; TX,
transplantation; WBC, white blood cell; bw, body weight; A, HLA-A; B, HLA-B; DR, HLA-DRB1; DQ, HLA-DQB1.
Note: Not all parameters are in all patients available.
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and compared using the unpaired t-test with
GraphPad-Prism software (Graph Pad Software, La
Jolla, Ca). Furthermore, we compared the median size
of the graft according to WBC, CD341 cells, and
CD31 cells/kg recipient bw in each graft source group.RESULTS
Engraftment
All patients achieved engraftment with WBC
counts $ 1  109/L by median day 117 (range,
12-28 days) after BMT and by median day114 (range,
10-30 days) after PBSCT (P\ .05), except for one pa-
tient with AML after primary induction failure who
died on day112 of pulmonary hemorrhage before en-
graftment after BMT. No primary or secondary graft
failure occurred. Stable platelet counts $20  109/L
and $50  109/L after BMT were reached by median
day 127 (range, 14-100 days; n 5 36) and median day
134 (range, 22-204 days; n 5 34), respectively. The
values after PBSCT were median day 117 (range,
9-79 days; n 5 41; P \ .001) and day 123 (range,
15-97 days; n5 35; P5 .0005), for engrafting patients
only. Eight patients died before stable platelet engraft-
ment (Table 3).
Response
At day130, CR was achieved by standard diagnos-
tic procedures in 78 of 85 evaluable patients (92%) and
partial remission (PR) in two of 85 patients (2%). One
patient was refractory, and four patients died before
day 130. No difference in response was observed
regarding the graft source BM (CR, 38 of 43
patients; 88%) vs PBSC (CR, 40 of 42 patients; 95%).
Graft-versus-Host Disease
Clinically relevant aGVHD II to IV developed in
19 of 84 patients (27%) and GVHD III to IV in sevenof 84 evaluable patients (8%) after engraftment. One
patient, who died before engraftment, was excluded.
Limited cGVHD was observed in 12 patients and
extensive cGVHD in 25 patients. Cumulative
incidence rates for cGVHD after 12 months were esti-
mated as 32.6% (95%CI, 21.2%-50.1%) for BMT and
52.4% (95% CI, 39.3%-69.9%) for PBSCT (P5 .11).Outcome According to Graft Source
As of March 1, 2010, 41 of 85 patients (48%) were
alive with a median follow-up of nearly 10 years
(118 months; range, 68-174 months). For all patients,
10-year OS rates estimated by the Kaplan-Meier
method are 30.2% (95% CI, 16.5%-44%) for BMT,
and 59.5% (95% CI, 44.7%-74.4%; P 5 .0029) for
PBSCT (Figure 1). The cumulative 10-year EFS rate
after PBSCT was estimated to be 54.8% (95% CI,
39.7%-69.8%) and after BMT 27.9% (95% CI,
14.5%-41.3%; P\ .004) (Figure 2).
Thirty patients relapsed. Second transplantation
was performed in nine patients; two of them achieved
sustained CR. Multiple donor lymphocyte transfu-
sions were given to 12 patients; only one patient
(8%) responded with a long-lasting CR.
Relapse was the leading cause of death in 25 of 85
patients (29%), followed by infection in eight of 85 pa-
tients (9%) and multiorgan failure or acute respiratory
distress syndrome in six of 85 patients (7%). One pa-
tient died from aGVHD (1%), and five of 85 patients
(6%) died from cGvHD. Other causes were diffuse
hemorrhage and secondary malignancy in one patient
each.
The cumulative incidence rate of NRM at 5 years
was 14.3% (95% CI, 7%-30%) in the PBSCT group
and 30.2% (95% CI, 19%-48%) in the BMT group.
Relapse was the cause of death in 15 of 43 in the
BMT group and eight of 42 in the PBSCT group
with a cumulative incidence at 5 years of 32.6%
(95% CI, 21%-50%) and 23.8% (95% CI, 14%-
41%), respectively (Figure 3A and B).
Table 3. Results and Outcome
Number
BMT (n 5 43) PBSCT (n 5 42)
CR1/RA Advanced CR1/RA Advanced
9 34 16 26
Engraftment (day+)
WBC (range)
>0.5  109/L 15 (13-21) 17 (10-24) 14.5 (11-24) 12 (9-17)
>1  109/L 16 (14-22) 17 (12-28) 16.5 (12-30) 12.5 (10-19)
Platelets
>20  109/L 30 (16-63) 25 (14-100) 18 (14-30) 16 (9-79)
>50  109/L 86 (22-172) 33.5 (22-204) 23 (17-48) 24 (15-9)
CMV reactivation 6 20 9 16
Best response
CR 9 29 16 24
PR 1 1
Refractory 1
Not evaluable 3
aGVHD (n) 9 33 16 26
0-I 8 (89%) 25 (75%) 15 (94%) 17 (65%)
II-IV 1 (11%) 8 (25%) 1 (6%) 9 (35%)
III-IV 1 (3%) 6 (23%)
Not evaluable 1
cGVHD (n)
No 3 (33%) 15 (63%) 11 (29%) 8 (33%)
Limited 1 (11%) 3 (13%) 3 (19%) 4 (17%)
Extensive 5 (55%) 6 (25%) 2 (13%) 12 (50%)
Not evaluable 10 2
Follow-up 1.3.2010
Alive (n) 4/9 9/34 11/16 14/26
Months (in median) 147 145 81 111
Range (126-169) (109-174) (69-132) (68-129)
Causes of death (n)
Relapse 4 11 5 5
aGVHD 1
cGVHD 1 1 3
MOF/ARDS 3/3
Infection 5 3
Hemorrhage 1
Secondary malignancy 1
BMT indicates bone marrow transplantation; PBSCT, peripheral blood stem cell transplantation; WBC, white blood cell; CMV, cytomegalovirus; CR,
complete response; PR, partial response; aGVHD, acute graft-versus-host disease; n, evaluable patients; cGVHD, chronic graft-versus-host disease;
MOF, multiorgan failure; ARDS, acute respiratory distress syndrome.
Note: Not all parameters are available in all patients, and not all patients reached $20  109/L platelets.
Figure 1. Overall survival comparing all patients (n5 85) and patients
with .CR1 (n 5 60) according to graft source (bone marrow [BM] vs
peripheral blood stem cell transplantation [PBSCT]).
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Patients
Univariate regression analysis with Cox propor-
tional hazard models for OS in all patients (n 5
85) revealed a significant influence of the graft
source in favor of PBSC (HR, 0.42; 95% CI,
0.23-0.75; P 5 .004) and showed a disadvantage
for disease status at HCT .CR1 (HR, 2.18; 95%
CI, 1.08-4.38; P 5 .03) and for $1 cytogenetic un-
favorable/unknown prognostic impact abnormalities
(HR, 1.74; 95% CI, 0.93-3.27; P 5 .08). No other
significant differences could be shown regarding
sex, female donor in male recipient, age at HCT
(\40 years vs $40 years), ATG-F dose ($60 mg/
kg bw vs\60 mg/kg bw), and CMV serology of do-
nor/patient and cGVHD. We noted a statistical
trend for a better OS with an HLA-mismatched do-
nor and negative CMV serology in the patient
(Table 4A).Within each group (BM vs PBSC), we did not
observe any statistically significant difference concern-
ing the transplanted median WBC, CD31, or CD341
cell doses/kg bw.
Figure 2. Event-free survival comparing all patients (n 5 85) and pa-
tients with .CR1 (n 5 60) according to graft source (bone marrow
[BM] vs peripheral blood stem cell transplantation [PBSCT]).
Figure 3. Cumulative relapse (A) and nonrelapse mortality (B) inci-
dence comparing all patients (n 5 85) according to graft source (bone
marrow [BM] vs peripheral blood stem cell transplantation [PBSCT]).
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95% CI, 0.24-0.8; P 5 .007) remained as a positive
prognostic factor. The strongest negative influence
on outcome was active/advanced disease at HCT
(HR, 2.37; 95% CI, 1.16-4.86; P 5 .018) and the
presence of unfavorable/unknown prognostic impact
cytogenetic abnormalities (HR, 2.2; 95% CI,
1.19-4.06; P 5 .012). Additionally, and in line with
published risk factors, patients with positive CMV
serology had a trend to decreased survival (HR, 1.85;
95% CI, 0.93-3.66; P 5 .078) (Table 4B).
Univariate and Multivariate Analysis in Patients
with Advanced/Active Disease
In the active/advanced disease group (n 5 60),
univariate analysis revealed a significant advantage
for PBSCT (HR, 0.42; 95% CI, 0.21-0.84; P 5 .015)
(Figure 1). OS was significantly decreased with unfa-
vorable/unknown prognostic impact cytogenetic
abnormalities (HR, 3.13; 95% CI, 1.51-6.49; P 5
.0021). All other analyzed parameters revealed no
significant effect (Table 5A).
This statistical effect of the graft source was weaker
in the multivariate analysis but still remained signifi-
cant (HR, 0.491; 95% CI, 0.24-0.99; P 5 .0461).
Again, abnormal cytogenetics at diagnosis continued
to provide the strongest statistical significance for
survival impairment (HR, 2.68; 95% CI, 1.33-5.40;
P 5 .0057) (Table 5B). Survival in the CR1 group
showed no difference according to the graft source
(data not shown).DISCUSSION
Our retrospective analysis of 85 consecutive
patients with AML and MDS after conventional,
myeloablative conditioning and URD transplantation
in early or active/advanced disease indicated a signifi-
cant benefit for the use of PBSC compared to BM.
This is in contrast to a Spanish database survey for
sibling alloHCT, which showed no difference accord-
ing to OS [26] but is in line with a meta-analysis insibling HCT [6] and with a validated Markov model
analysis, which shows an advantage for PBSC in
patients with an increased risk of relapse [27]. Further-
more, we also demonstrated a faster engraftment in
URD transplantation after PBSC for neutrophils and
platelets [2,28]. Such an analysis in a uniformly
treated patient collective after URD has not been
performed before with such long patient follow-up of
almost 10 years. The data contradict published inves-
tigations in sibling transplantations in randomized tri-
als [6,29,30] and recently published registry data for
URD transplantation [19] for various hematologic
malignancies, which showed no difference between
the graft sources for OS and EFS. Higher incidence
of NRM is seen by the Japanese Society for HCTReg-
istry in a recent published analysis for standard-risk pa-
tients after sibling donor HCT but not for high-risk
patients [31]. Chronic GVHD has been suspected to
cause the higher rate of late NRM [19]. In our patients,
cGVHDwas the cause of only one late death in the last
5 years (2006-2010) associated with NRM.
Moreover, we could confirm the prognostic
importance of cytogenetic aberration evaluation in
myeloid diseases at diagnosis of AML/MDS to desig-
nate patients at risk for poor outcome [32-34].
We performed univariate and multivariate Cox
regression analysis with known prognostic factors for
OS, but except for remission at alloHCT and cytoge-
netic abnormalities, no other parameters proved to be
statistically significant in our analysis. Interestingly, in
contrast to published sibling-transplantation data, we
observed no statistically significant effects for the
incidence of cGVHD, [4,8] positive-CMV serology
of the patient, [9] female donor and male recipient,
Table 4. Univariate (A) and Multivariate (B) Analysis of
Prognostic Factors for OS in All Patients (n 5 85)
A
Hazard
Ratio
95% CI
Lower Limit
95% CI
Upper Limit
P
Value
Remission at TX
Advanced vs early 2.176 1.080 4.383 .0296
Cytogenetics
Unfavorable/unknown dignity 1.742 0.929 3.267 .0834
HLA mismatch
Yes vs no 1.613 0.888 2.929 .1164
CMV serology
Patient positive vs negative 1.651 0.840 3.246 .1461
Gender patient
Male 1.286 0.725 2.282 .3895
CMV serology
Donor positive 1.181 0.646 2.159 .5894
Age at TX
$40 years 1.021 0.576 1.810 .9422
Sex mismatch
Patient male, donor female 1.019 0.518 2.002 .9572
Time period
2000-2004 vs 1995-1999 0.646 0.363 1.150 .1375
Chronic GVHD
Yes, time dependent 0.897 0.440 1.829 .7657
Graft
PBSC vs BM 0.415 0.228 0.754 .0039
B
Hazard
Ratio
95% CI
Lower Limit
95% CI
Upper Limit
P
Value
Remission at TX
Advanced vs early 2.372 1.158 4.858 .0182
Cytogenetics
Unfavorable/unknown dignity 2.202 1.194 4.061 .0115
CMV serology
Patient CMV positive 1.850 0.934 3.663 .0776
Graft
PBSC vs BM 0.433 0.236 0.796 .0070
OS indicates overall survival; CI, confidence interval; TX, transplanta-
tion; CMV, cytomegalovirus; GVHD, graft-versus-host disease; PBSC,
peripheral blood stem cell; BM, bone marrow.
Only variables with significant or trend differences listed.
Table 5. Univariate (A) and Multivariate (B) Analysis of
Prognostic Factors for OS in Advanced Disease Patients (n 5
60)
A
Hazard
Ratio
95% CI
Lower Limit
95% CI
Upper Limit
P
Value
Cytogenetics
Unfavorable/unknown dignity 3.134 1.513 6.492 .0021
CMV serology
Patient positive 1.443 0.698 2.983 .3226
Patient gender
Male 1.362 0.712 2.602 .3502
HLA mismatch
Yes 1.353 0.701 2.612 .3678
Age at TX
$40 years 1.168 0.612 2.228 .6381
CMV serology
Donor positive 1.045 0.532 2.053 .8975
Chronic GVHD
Yes, time dependent 1.031 0.450 2.361 .9424
Sex mismatch
Patient male, donor female 0.900 0.395 2.050 .8012
Time period
2000-2004 vs 1995-1999 0.629 0.323 1.224 .1723
Graft
PBSC vs BM 0.421 0.211 0.842 .0145
B
Hazard
Ratio
95% CI
Lower Limit
95% CI
Upper Limit
P
Value
Cytogenetics
Unfavorable/unknown dignity 2.683 1.333 5.401 .0057
Graft
PBSC vs BM 0.491 0.244 0.988 .0461
OS indicates overall survival; CI, confidence interval; CMV, cytomegalo-
virus; TX, transplantation; GVHD, graft-versus-host disease; PBSC, pe-
ripheral blood stem cell; BM, bone marrow.
Only variables with significant or trend differences are listed.
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cell dose) [10-13]. Regarding the graft source, a clear
statistical advantage for improved survival in favor
for PBSC could be observed.
All patients received ATG-F for GVHD prophy-
laxis, which in our opinion, is responsible for our low
incidence of aGVHD and the low NRM rate due to
GVHD [20] compared to the mentioned registry
evaluation [19]. This has been shown in a large ran-
domized study comparing ATG-F vs no ATG-F [20]
and in two recently published surveys of the Center
for International Blood and Marrow Transplant
Research (CIBMTR) [28] and the French Transplant
Group [35]. Our prophylaxis led to equal results in
matched and mismatched transplantations [22]. Addi-
tionally, it is notable that the transplantations were
performed only with antigen-matched HLA class I
typing (two-digit) in contrast to the current high-
resolution testing (four-digit allele). The comparisonof different doses of ATG-F showed no difference;
hence, lower doses (\60 mg/kg) may suffice to prevent
aGVHD.
Lower NRM and relapse rates are responsible
for the better OS observed in patients with active/
advanced disease undergoing PBSCT. We assume
that the higher dose of transplanted T cells in
patients in the PBSC group led to a higher cumula-
tive incidence of cGVHD at 12 months (32.6% vs
52.4%), indicating a statistical trend in our analyses;
this trend has been published in URDs before
[16,17]. Why the patients receiving PBSC had
a lower NRM is unclear.
Of note, when comparing our data with study
results involving sibling donors, our patients present
a particularly negative selection when one considers
their adverse cytogenetics (52%), those with persistent
induction failure (22%), and those in relapse before
HCT (28%). Therefore, we do not agree with a review
[36] where palliative care only is suggested for these
patients. In contrast, despite these poor prognostic
factors in our patients, we achieve long-term CR.
Biol Blood Marrow Transplant 18:894-902, 2012 901BMT versus PBSCT in Active Myeloid MalignanciesIn fact, our long-term survival results concur with data
raised in matched sibling transplantations in patients
\56 years with similar cytogenetic risks and a DFS
of 52% after 5 years [21].
We have conducted a retrospective analysis of
nonrandomized patients, and we are aware that this
may result in possibly biased effect estimation. Besides
the prognostic factors considered in our investigations,
time of transplantation differed between graft sources
and may thus have added to a possible bias, because
better supportive care was available. However, the
application of multivariate regression methods may
alleviate these shortcomings. Furthermore, our data
have a notably long observation time with a median
follow-up of nearly 10 years. Therefore, our investiga-
tion contributes important information to the choice
of the graft source.
We thus conclude that an early search at initial di-
agnosis should be performed for aURD in each patient
with myeloid malignancy. Furthermore, PBSC should
be the graft of choice in URD transplantation in
patients with active, advanced myeloid disease, receiv-
ing ATG-F as part of their GVHD prophylaxis.
We are waiting for the results of a large random-
ized trial comparing BM and PBSC inURD transplan-
tation (BMT CTN 0201). The enrollment was
completed in September 2009 [37].ACKNOWLEDGMENT
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